Stockscreener 앱 받기
2.69
3.07%
0.08
시간 외 거래:
2.67
-0.02
-0.74%
전일 마감가:
$2.61
열려 있는:
$2.65
하루 거래량:
244.62K
Relative Volume:
2.18
시가총액:
$91.52M
수익:
$210.00K
순이익/손실:
$-10.40M
주가수익비율:
-8.5424
EPS:
-0.3149
순현금흐름:
$-6.88M
1주 성능:
+14.47%
1개월 성능:
-4.61%
6개월 성능:
-17.61%
1년 성능:
-26.90%
1일 변동 폭
$2.53
$2.785
1주일 범위
$2.32
$2.785
52주 변동 폭
$2.32
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
명칭
Anixa Biosciences Inc
전화
408-708-9808
주소
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.69 | 84.38M | 210.00K | -10.40M | -6.88M | -0.3149 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 개시 | Maxim Group | Buy |
| 2022-12-23 | 개시 | Chardan Capital Markets | Buy |
| 2021-04-12 | 개시 | H.C. Wainwright | Buy |
Anixa Biosciences Inc 주식(ANIX)의 최신 뉴스
12 Health Care Stocks Moving In Monday's After-Market SessionAlvotech (NASDAQ:ALVO), Anixa Biosciences - Benzinga
ANIX Q1 2026 Earnings: Narrower-than-expected loss highlights disciplined spending amid clinical developmentGuidance Update - newsline.com
Anixa Biosciences (ANIX) Holds Near Key Support After Marginal DeclineRisk Reversal - newsline.com
H.C. Wainwright reiterates Buy on Anixa stock, $7 target By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy on Anixa stock, $7 target - Investing.com
Anixa Biosciences, Inc. (ANIX) Stock Price, News, Quote & History - Yahoo Finance
Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium - PR Newswire
Anixa Biosciences Inc 3Q 2026: Net loss $(2.52M), EPS $(0.07) — 10-Q Summary - TradingView
Anixa Biosciences (NASDAQ: ANIX) trims losses and details cancer pipeline - Stock Titan
Number of shareholders of Anixa Biosciences, Inc. – GETTEX:CY71 - TradingView
Anixa Biosciences Holds Steady Near Support as Trading Volume Remains SubduedSuperTrend - The Legal Advocate
Anixa Biosciences (ANIX) Secures Patent for Ovarian Cancer Vacci - GuruFocus
Anixa Biosciences (ANIX) Secures Patent for Ovarian Cancer Vaccine Technology - GuruFocus
Anixa receives Canadian patent allowance for ovarian cancer vaccine By Investing.com - Investing.com Nigeria
Anixa receives Canadian patent allowance for ovarian cancer vaccine - Investing.com
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance - PR Newswire
Anixa Biosciences (ANIX) Edges Higher, Tests Key Support ZoneQuality Factor - The Legal Advocate
Anixa Biosciences (ANIX) Holds Steady at $2.73 as Consolidation ContinuesMomentum ETF - The Legal Advocate
Anixa Biosciences (ANIX) Slides 2.15% as Biotech Sector Headwinds ReturnPrice Action Signals - The Legal Advocate
Anixa Biosciences (ANIX) Edges Higher on Above-Average Volume, Testing Key ResistanceGap and Go - newsline.com
Anixa Biosciences Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ANIX Stock Price, Quote & Chart | ANIXA BIOSCIENCES INC (NASDAQ:ANIX) - ChartMill
Anixa Biosciences Issues Correction to May 11, 2026 Announcement, Details Available on StockTitan.net - geneonline.com
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-Cel Ovarian Cancer Car-T Therapy - marketscreener.com
Anixa Biosciences (ANIX) Reports Promising Survival Data from Cl - GuruFocus
Anixa reports survival data from ovarian cancer therapy trial - Investing.com UK
/C O R R E C T I O N -- Anixa Biosciences, Inc./ - PR Newswire
Anixa reports survival data from ovarian cancer therapy trial By Investing.com - Investing.com Australia
Anixa Biosciences Reports Updated Positive Survival Observations From Ongoing Phase 1 Trial Of Lira-Cel Ovarian Cancer CAR-T Therapy - TradingView
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy - StreetInsider
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer - Quantisnow
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat - Quantisnow
Anixa Biosciences (NASDAQ:ANIX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - The Malaysian Reserve
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - Investing News Network
Bloomberg TV to air Anixa CEO on cancer vaccine and CAR-T data - Stock Titan
Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ChartMill
Anixa Biosciences announces issuance of Mexican patent covering breast cancer vaccine technology - marketscreener.com
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology - The AI Journal
Anixa Biosciences (ANIX) Secures Patent for Breast Cancer Vaccine Technology - GuruFocus
Anixa Biosciences receives Mexican patent for breast cancer vaccine By Investing.com - Investing.com Australia
Anixa Biosciences receives Mexican patent for breast cancer vaccine - Investing.com
A breast cancer vaccine gained patent protection in Mexico until 2040 - Stock Titan
Anixa’s ovarian cancer therapy to be presented at ISCT meeting By Investing.com - Investing.com India
Anixa’s ovarian cancer therapy to be presented at ISCT meeting - Investing.com
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting - Nasdaq
Anixa Biosciences Inc (ANIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anixa Biosciences Inc 주식 (ANIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Baskies Arnold M | Director |
Jan 28 '26 |
Buy |
3.04 |
10,000 |
30,400 |
135,000 |
| Titterton Lewis H jr | Director |
Dec 15 '25 |
Option Exercise |
2.92 |
16,000 |
46,720 |
969,334 |
| KUMAR AMIT | Chief Executive Officer |
Oct 30 '25 |
Option Exercise |
2.92 |
200,000 |
584,000 |
779,925 |
| Titterton Lewis H jr | Director |
Jul 31 '25 |
Buy |
3.08 |
10,000 |
30,800 |
953,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
2.60%
0.94%
자본화:
|
볼륨(24시간):